

COVID-19 Immunization Screening and Consent Form*

Recipient Name (please print)		Preferred Name						
DOI	Current Gender ID Key:							
DO	W – Woman	/Girl TW – Transgender Wom	an/Girl M	– M	an/Bo	у		
	Indicate ID Below: TM – Trans	gender Man/Boy NB – Non-Bin	ary Person	GN	IC – G	end	ler No	n-Conforming
		e/Questioning NR – Chose r	=					
		er not Listed (write-in)						
	* Gender Pr	onouns: write-in by client's nam	е					
	Assigned at Birth Key:	Marital Status Ke	-					
Indi	cate Sex Below:		U		Divor			– Married
	M – Male F – Female	II I	– Widowed					Jnknown
	I – Intersex NR – Chose not to Respond	II I	PARATED – L ARTNER – Life	_		oara	itea	
۸۵۵	lress City	State Zip	Email Addr		tilei			
Auc	iless City	State Zip	Elliali Auul	C 33				
	./0 !: /0 // !:		5 6 11					
Par	ent/Guardian/ Surrogate (if applicable, please print)	Phone	Preferred L	.angı	uage			
C+b.	pinitu. Filosiais Vous	Page Page Vo	\ <u>'</u>					
	nicity Ethnicity Key: cate Ethnicity Below: DECL – Declined	Race Race Key: Indicate Race Below: AIA – Native American or Alaskan ASN – Asian						
IIIui	HIS – Hispanic Origin		frican Americ				٨٥١	Asian
	NHL – Non-Hispanic Origin	DECL – D						
	UNK – Unknown	NHP – N	ative Hawaiia	an o	r Pacif	fic Is	slande	er
		WHT – V	Vhite		0	ГН -	- Othe	r or Multiracial
Prin	nary Insurance Name	Primary Insurance ID# Subscriber		Name/DOB Su			Subs	criber Relation
							to P	atient
Prin	nary Insurance Address	Primary Insurance Group #	Primary Ins	surar	nce Ph	one	e #	
			- 1 11		/			
Sec	ondary Insurance Name	Secondary Insurance ID#	Subscriber	Nam	ne/DC	В		scriber Relation
							to P	atient
Sec	ondary Insurance Address	Secondary Insurance Group #	Secondary	Incu	ranco	Dh	one #	
360	ondary modrance Address	Secondary madrance Group #	Secondary	IIISU	Tarice		one #	
Clin	ic/Office Site Where Vaccine is Administered	Primary Care Physician Address	l s/Phone Num	nher				
			,					
	Scree	ening Questionnaire						
1.	Are you feeling sick today?	_			Yes		No	
2.	In the last 10 days, have you had a COVID-19 tes	t hecause you had symptoms a	nd are still		Yes			□ Unknown
۷.	awaiting your test results or been told by a heal				162		No	- OHKHOWH
	isolate or quarantine at home due to COVID-19 infe							
3.	Have you been treated with antibody therapy or con	valescent plasma for COVID-19 in	the past 90		Yes		No	□ Unknown
	days (3 months)? If yes, when did you receive the la		_					
4.	Have you ever had an immediate allergic reaction (e		– v hreathing		Yes		No	□ Unknown
-т.	anaphylaxis) to any vaccine, injection, or shot or to a				103		140	
	severe allergic reaction (anaphylaxis) to anything?	, ,	,					
5.	Are you pregnant or considering becoming pregnar	nt?			Yes		No	□ Unknown
٥.	- , p			ı –	. 23	ı_		

6.	Do you have cancer, leukemia, HIV/AIDS or any other condition that weakens the immune system?		Yes	No	□ Unknown
7.	Do you take any medications that affect your immune system, such as cortisone, prednisone or other steroids, anticancer drugs, or have you had any radiation treatments?		Yes	No	□ Unknown
8.	Do you have a bleeding disorder, a history of blood clots or are you taking a blood thinner?	□ Yes □ No □ Unkno		□ Unknown	
9.	Do you have a history of myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining around the heart)?		Yes	No	□ Unknown
10. *	Are you 12 years old or older, and have you received 2 doses of the Pfizer vaccine, the second dose being at least 5 months ago?		Yes	No	Date of 2 nd dose:
11.	Have you received 2 doses of the Moderna vaccine, the second dose being at least 5 months ago?		Yes	No	Date of 2 nd dose:
12.	Have you received a previous dose of the Janssen vaccine, at least 2 months ago?		Yes	No	Date of 1st dose:
13.	If you had a previous dose of Janssen (Johnson & Johnson), did you develop thrombosis with thrombocytopenia syndrome (TTS)?		Yes	No	□ Unknown
14.1	Have you received a previous dose of a non-FDA authorized or approved COVID-19 vaccine authorized by the WHO¹ but not by the FDA (AstraZeneca – VAXZEVRIA, Sinovac – CORONAVAC, Serum Institute of India – COVISHIELD, Sinopharm/BIBP, COVAXIN, Novavax – Covovax, Nuvaxovid)?		Yes	No	□Unknown

^{*}Questions #10 - 14 pertain to booster dose eligibility.

Emergency Use Authorization

The FDA has made the COVID-19 vaccine available under an emergency use authorization (EUA). The EUA is used when circumstances exist to justify the emergency use of drugs and biological products during an emergency, such as the COVID-19 pandemic. This vaccine has not undergone the same type of review as an FDA-approved or cleared product. However, the FDA's decision to make the vaccine available is based on the totality of scientific evidence available, showing that known and potential benefits of the vaccine outweigh the known and potential risks. Please note: FDA approved the Pfizer-BioNTech COVID-19 vaccine as a two-dose series in individuals 16 years of age and older. The vaccine continues to be available under an EUA for certain populations, including for those individuals 5 through 15 years of age and for the administration of a third dose in the populations set forth in the consent section below.

Emergency Use Instruction

Emergency Use Instructions (EUIs) are issued by the CDC to provide information about emergency use of FDA-approved medical products that may not be included in or differ in some way from the information provided in the FDA-approved labeling (package insert). The COVID-19 vaccine by Pfizer-BioNTech is an FDA-approved COVID-19 vaccine (brand name Comirnaty, mRNA) to prevent COVID-19 in persons 16 years of age and older. CDC is issuing EUI to provide information about use of this vaccine as an additional primary dose in certain immunocompromised persons (12 years of age and older) and a booster dose in certain adults (18 years of age and older) who received certain **non-FDA authorized or approved COVID-19 vaccine** (e.g., certain vaccines available outside of the United States or from clinical trial participation).

Consent

I have read, or had explained to me, the information sheet about the COVID-19 vaccination. I understand that if my vaccine requires two doses, I will need to be administered (given) two doses to be considered fully vaccinated. Further, I understand that a booster dose of COVID-19 vaccine is recommended at least 2 months following the first dose of Janssen vaccine (if I am age 18 or older), or at least 5 months following the second dose of Pfizer-BioNTech (if I am age 5 or older) or Moderna COVID-19 vaccine (if I am age 18 or older), to increase my protection.

I have had a chance to ask questions which were answered to my satisfaction (and ensured the person named above for whom I am authorized to provide surrogate consent was also given a chance to ask questions). I understand the benefits and risks of the vaccination as described.

I request that the COVID-19 vaccination be given to me (or the person named above for whom I am authorized to make this request and provide surrogate consent). I understand there will be no cost to me for this vaccine. I understand that any monies or benefits for administering the vaccine will be assigned and transferred to the vaccinating provider, including benefits/monies from my health plan, Medicare or other third parties who are financially responsible for my medical care. I authorize release of all information needed (including but not limited to medical records, copies of claims and itemized bills) to verify payment and as needed for other public health purposes, including reporting to applicable vaccine registries.

¹ As set forth in the <u>CDC's Emergency Use Instructions</u>, a non-FDA authorized or approved COVID-19 vaccine such as those vaccines "listed for emergency use by the World Health Organization, or is included in CDC's Technical Instructions for Implementing Presidential Proclamation Advancing Safe Resumption of Global Travel During the COVID-19 Pandemic and CDC's Order, or that is a non-placebo part of a clinical trial within or outside the United States that is a WHO-EUL COVID-19 vaccine or a vaccine that is not listed for emergency use by WHO but for which a U.S. data and safety monitoring board or equivalent has independently confirmed efficacy in the United States (hereinafter "non-FDA authorized or approved COVID-19 vaccines").

Recipient/Surrogate/G recipient	uardian (Signature)	Date / Time Print Name			ationship to Patient ther than recipient)
Telephonic Interpreter' OR	s ID#	Date / Time			
Signature: Interpreter		Date/ Time	Print: Interpret	er's Name and Relationship	to Patient
			e Completed by	Vaccinator	
Which vaccine is the	e patient receiving t	-		T	
Vaccine Name		Administratio	on	EUA Fact Sheet Date	Manufacturer & Lot #
Pfizer/BioNTech	□ First Dose	☐ Second Dose	□ Booster Dose		
Moderna	□ First Dose	☐ Second Dose	□ Booster Dose		
Janssen	☐ Single Dose	□ Booster Dose			
Administration Site	Left Deltoid	Right Delt	oid 🗆 Left Thi	gh 🗆 Right Thigh	
Dosage	□ 0.5 ml	□ 0.3 ml	□ 0.25 ml		
☐ I have provide and consent to vaccivator Signatur	cination was obtai	· · ·	n or surrogate, as a	oplicable) with informati	on about the vaccine
_					
lse of this form is o	ptional.			Updat	ed January 7, 2022